Vertex Pharmaceuticals Announces Publication of Phase 3 RAINIER Results for Povetacicept

Vertex Pharmaceuticals published the Phase 3 RAINIER study results for its investigational therapy povetacicept in the New England Journal of Medicine and presented the findings at the American Society of Nephrology Kidney Week 2026. The therapy is being evaluated for IgA nephropathy (IgAN), with management emphasizing its efficacy, safety profile, and convenient dosing schedule during an investor event.